Advertisement

Topics

Amura Therapeutics Ltd Company Profile

12:42 EST 21st January 2019 | BioPortfolio

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:
An Osteoporosis programme based on cathepsin K inhibitors
A Psoriasis programme based on a cathepsin S inhibitors
A Rheumatoid Arthritis programme based on cathepsin S inhibitors
A Malaria programme based on falcipain inhibitors
Additionally Amura has an antibacterial programme based on beta-lactamase inhibitors.
From its ProtoDiscovery™ platform Amura has four target-specific design programmes in the GPCR area:
5HT1A agonists
5HT1A antagonists
MC4R
MCH1
Amura will out-license its discovery programmes at the pre-clinical stage.
Amura also has a service-based operation providing in silico screening and design of small molecule ligands

Location

Barton Road
Comberton
Cambridgeshire
CB3 7AJ
United Kingdom

Contact

Phone: 44 (0)1223 265265
Fax: 44 (0)1223 265266
Email: amura@amura.co.uk


News Articles [647 Associated News Articles listed on BioPortfolio]

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As thi...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact The...

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for an initial public offering. The company plans to offer 1.75mm shares at a $...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [Kastle Therapeutics, LLC]

NA

Olopatadine hydrochloride [Somerset Therapeutics, LLC]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [Breathe Easy Therapeutics, Inc]

NA

Diclofenac sodium delayed release [Cambridge Therapeutics Technologies, LLC]

Diclofenac Sodium

Olopatadine hydrochloride [A-S Medication Solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [471 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1295 Associated Companies listed on BioPortfolio]

Amura Therapeutics Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design...

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design...

Amura Limited

Amura Limited is an early stage, privately owned, anti-infectives company specialising in novel antibiotics to combat moderate to severe infections. The company is based in Histon, Cambridge and opera...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Amura Therapeutics Ltd" on BioPortfolio

We have published hundreds of Amura Therapeutics Ltd news stories on BioPortfolio along with dozens of Amura Therapeutics Ltd Clinical Trials and PubMed Articles about Amura Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Amura Therapeutics Ltd Companies in our database. You can also find out about relevant Amura Therapeutics Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record